Better Context → Better Decisions
Context counts in life sciences. The FENIX analyst team is tirelessly using its experience to put you in a position to succeed. Below, our readers without corporate access will find a wealth of contextualized life science insight ready to be purchased in the FENIX Marketplace. If our content sharing limitations are inconvenient for you, reach out to Brady for unlimited corporate, institutional, or individual access.
$599
Posted in: Basal Insulin, Bolus Insulin, Other Nov 29 | 2022Biocon Completes Viatris Biosimilars Business Acquisition; Nemaura Launches Miboko Pilot Program in UK; BMS Terminates CV Partnership with uniQurePurchase Blast
$599
Posted in: Glucose Monitoring, Insulin Delivery, Other Nov 28 | 2022Libre 3 + Ypsomed AID Authorized in Germany; Diamyd Ph3 T1DM Clinical Hold LiftedPurchase Blast
$599
Posted in: Basal Insulin, GLP-1RA + Basal, Glucose Monitoring, Insulin Delivery, SGLT2i Nov 23 | 2022Medtronic CY Q3 ’22 Earnings Update; Novo Expands Manufacturing Facilities; FDA Approves Lilly’s Rezvoglar as an Interchangeable Biosimilar; Oramed Presents Additional Ph2 PRMD-0801 NASH DataPurchase Blast
$599
Posted in: Other Nov 17 | 2022Teplizumab Approved as Tzield; Sernova Implants First Two Patients in Second Cohort of Ph1/2 T1DM TrialPurchase Blast
$599
Posted in: Insulin Delivery, Other Nov 16 | 2022Medtronic Launches Extended Wear Infusion Set; Dario Q3 ’22 Earnings Update; Versanis Bio Initiates Ph2 Bimagrumab Study in ObesityPurchase Blast
$599
Posted in: Basal Insulin, Bolus Insulin, Glucose Monitoring, Insulin Delivery Nov 15 | 2022Lilly and Novo Leave Twitter Advertising; Insulet Issues O5 Medical Device Correction; Biocon, Movano, and Nemaura Q3 ’22 Earnings UpdatesPurchase Blast
$599
Posted in: Other Nov 11 | 2022Tandem Reports Positive Results from Control-IQ T2DM Feasibility StudyPurchase Blast
$599
Posted in: Glucagon, Insulin Delivery, Other, SGLT2i Nov 11 | 2022AZ and Zealand Q3 ’22 Earnings Updates; Novo Smart Pen Integration with LibrePurchase Blast
$599
Posted in: Glucagon, Other, SGLT2i Nov 09 | 2022Lexicon, Xeris, and Ionis Q3 ’22 Earnings Updates; Esperion Hosts 2022 R&D DayPurchase Blast
$599
Posted in: GLP-1RA, Glucose Monitoring, Other Nov 08 | 2022Amgen Post-AHA 2022 Pipeline Update; Senseonics, Bayer, and MannKind Q3 ’22 Earnings UpdatesPurchase Blast
$599
Posted in: Glucose Monitoring, Insulin Delivery, Other Nov 07 | 2022Lilly Connected Pen US Launch in 2022; Lannett Partners with Ypsomed; Eversense to Integrate with Apple; Viatris Q3 ’22 Earnings Update; November CHMP AgendaPurchase Blast
$599
Posted in: Other, SGLT2i Nov 04 | 2022EMPA-KIDNEY Demonstrates 28% RRR @ ASN 2022; Sernova to Expand Ph1/2 Patient Cohort; Creative Medical Cell Therapy IND Granted FDA Clearance; Senseonics/Ascensia Collaborate with NPG to Expand Eversense CGM Access; Amgen Q3 ’22 Earnings UpdatePurchase Blast
$599
Posted in: Insulin Delivery, Other Nov 03 | 2022Insulet, Provention Bio, Madrigal, and Regeneron Q3 ’22 Earnings UpdatesPurchase Blast
$599
Posted in: Basal Insulin, GLP-1RA, GLP-1RA + Basal, Other Nov 03 | 2022Novo Q3 ’22 London EarningsPurchase Blast
$599
Posted in: Basal Insulin, Bolus Insulin, Insulin Delivery Nov 02 | 2022Tandem and Lannett Q3 ’22 Earnings Updates; Indigo Expands into US; OrsoBio Acquires T2DM and NASH AssetsPurchase Blast$599
Posted in: Basal Insulin, GLP-1RA, Other Nov 02 | 2022Novo Nordisk Q3 ’22 Earnings Update; FY Guidance RaisedPurchase Blast
$599
Posted in: Basal Insulin, GLP-1RA, Other Nov 01 | 2022Pfizer, Esperion, and Intercept Q3 ’22 Earnings Updates; First Patient Dosed in Biomea’s Ph1/2 BMF-219 T2DM TrialPurchase Blast
$599
Posted in: Basal Insulin, Dual/triple agonist, Insulin Delivery, Other Nov 01 | 2022Lilly Q3 ’22 Earnings UpdatePurchase Blast
$599
Posted in: Basal Insulin, GLP-1RA, Other Oct 28 | 2022Vertex and Sanofi Q3 ’22 Earnings Updates; Sciwind Reports Positive Interim Results from Ph2b Ecnoglutide Obesity TrialPurchase BlastGet the Latest Analysis
Stay informed and aligned with frequent updates to keep a pulse on the industry.
If you already have an account, please log in. If you have any questions or would like to subscribe to our services, please contact Brady.
